GENELUX CORPORATION Depreciation
GENELUX CORPORATION (GNLX) reported Depreciation of $10.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-13
- GENELUX CORPORATION depreciation for the quarter ending 2026-06-30 was $10.00K, a 83.87% decline year-over-year.
- GENELUX CORPORATION depreciation for the quarter ending 2026-03-31 was $9.00K, a 84.75% decline year-over-year.
- GENELUX CORPORATION depreciation for the quarter ending 2025-12-31 was $60.00K, a 5.26% increase year-over-year.
- GENELUX CORPORATION depreciation for the quarter ending 2025-09-30 was $61.00K, a 8.93% increase year-over-year.
- GENELUX CORPORATION depreciation for fiscal 2025 was $244.00K, a 3.83% increase from fiscal 2024.
- GENELUX CORPORATION depreciation for fiscal 2024 was $235.00K, a 52.91% decline from fiscal 2023.
- GENELUX CORPORATION depreciation for fiscal 2023 was $499.00K, a 9.76% decline from fiscal 2022.
- GENELUX CORPORATION depreciation for fiscal 2022 was $553.00K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.00K 10-Q · filed 2026-08-13 | $20.00K 10-Q · filed 2026-08-13 | $79.00K derived: sum of 3 quarters · filed 2026-08-13 | $140.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $9.00K 10-Q · filed 2026-05-07 | $69.00K derived: sum of 2 quarters · filed 2026-05-07 | $130.00K derived: sum of 3 quarters · filed 2026-05-07 | $192.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $121.00K derived: sum of 2 quarters · filed 2026-03-19 | $183.00K derived: sum of 3 quarters · filed 2026-08-13 | $244.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $61.00K 10-Q · filed 2025-11-05 | $123.00K derived: sum of 2 quarters · filed 2026-08-13 | $184.00K 10-Q · filed 2025-11-05 | $239.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $62.00K 10-Q · filed 2026-08-13 | $122.00K 10-Q · filed 2026-08-13 | $178.00K derived: sum of 3 quarters · filed 2026-08-13 | $234.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $59.00K 10-Q · filed 2026-05-07 | $116.00K derived: sum of 2 quarters · filed 2026-05-07 | $172.00K derived: sum of 3 quarters · filed 2026-05-07 | $210.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $113.00K derived: sum of 2 quarters · filed 2026-03-19 | $151.00K derived: sum of 3 quarters · filed 2026-03-19 | $235.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $56.00K 10-Q · filed 2025-11-05 | $94.00K derived: sum of 2 quarters · filed 2025-11-05 | $178.00K 10-Q · filed 2025-11-05 | $273.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $122.00K 10-Q · filed 2025-08-07 | $217.00K derived: sum of 3 quarters · filed 2025-08-07 | $350.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $84.00K 10-Q · filed 2025-05-06 | $179.00K derived: sum of 2 quarters · filed 2025-05-06 | $312.00K derived: sum of 3 quarters · filed 2025-05-06 | $447.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $228.00K derived: sum of 2 quarters · filed 2025-03-28 | $363.00K derived: sum of 3 quarters · filed 2025-03-28 | $499.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $268.00K derived: sum of 2 quarters · filed 2024-11-14 | $404.00K 10-Q · filed 2024-11-14 | $542.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $271.00K 10-Q · filed 2024-08-14 | $409.00K derived: sum of 3 quarters · filed 2024-08-14 | $547.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $136.00K 10-Q · filed 2024-05-09 | $274.00K derived: sum of 2 quarters · filed 2024-05-09 | $412.00K derived: sum of 3 quarters · filed 2024-05-09 | $551.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $276.00K derived: sum of 2 quarters · filed 2024-03-29 | $415.00K derived: sum of 3 quarters · filed 2024-03-29 | $553.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $277.00K derived: sum of 2 quarters · filed 2023-11-14 | $415.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $277.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $138.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |